Targeted protein degradation(TPD)technology is an emerging approach that utilizes intracellu-lar proteasome or lysosome systems to eliminate disease-causing proteins,providing novel strategies for dis-ease treatment.Compared with conventional therapies,TPD has advantages such as targeting"undruppable"proteins,overcoming drug resistance and high selectivity.Among them,proteolysis-targeting chimeras(PRO-TACs)and molecular gels are representative methods,which have achieved significant progress in E3 ligase expansion,linker design,and delivery systems,and are gradually entering clinical research.PROTACs and mo-lecular glues can not only target key oncoproteins and overcome resistance,but also modulate immune respon-ses for therapeutic purposes,demonstrating broad clinical application prospects.This article reviews the re-search progress of the two types of technologies and their current application status in cancer treatment,and discusses their potential and challenges in efficacy monitoring and individualized medication from the perspec-tive of laboratory medicine.